Castration-Resistant Prostate Cancer
Castration-resistant prostate cancer (CRPC) is a form of prostate cancer that no longer responds to treatments that lower testosterone, allowing the cancer to grow and spread despite hormone therapy.
Advanced Prostate Cancer: 225Ac-PSMA-Trillium Study
We are testing a new treatment for men with advanced metastatic castration-resistant prostate cancer. This study aims to see how well it works and its safety in humans.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Nuclear Medicine
Heverlee, Belgium
Algemeen Ziekenhuis Groeninge
Urology
Kortrijk, Belgium
Institut Jules Bordet
Nuclear Medicine
Negenmanneke, Belgium
Sponsor: Bayer AG
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.